SlideShare a Scribd company logo
Mild versus conventional
ovarian stimulation for IVF/ICSI treatment
in women with poor ovarian reserve
(PRIMA Trial)
Youssef M.A.F.M
Al-Inany H.
Background
• The age of women giving birth to
their first child is rising
• Older women have decreased
fecundity
• Consequently, more older women
will request IVF
of poor ovarian response is 9-24%
Background
Broekmans et al. 2009 Endocrine Reviews
Conventional ovarian stimulationMild ovarian stimulation
Quality versus Quantity
Aim of PRIMA trial
• To evaluate the effectiveness and safety of a mild
stimulation IVF versus a conventional simulation IVF in
women with poor ovarian reserve undergoing IVF
treatment
394 couples poor ovarian reserve
197 couples
Mild IVF
197 couples
Conventional IVF
treatmenttime
OCP+ 150 IU FSH + GnRH
antagonist
Mid-Luteal Long GnRH agonist
+ 450 IU HMG
Ongoing Pregnancy
recruitme
nt
endpoint
PRIMA trial design
Couples
Inclusion criteria
•Women with an indication for IVF
•Aged > 35 years
•and/or women who have FSH >10 IU/ml
•and/or women who have AFC (< 7 follicles)
•Women who responded poorly during their 1st
IVF cycle irrespective
of their age.
Exclusion criteria
•Women with pre-existing medical conditions,
•Women > 43 years old;
•Women with uterine anomalies; polycystic ovary syndrome and
anovulation
450 IU HMG /day
mid-luteal GnRH agonist
hCG OPU ET
Menstr.
 Mild Ovarian stimulation IVF
 Conventional Ovarian stimulation/IVF
Interventions
150 IU FSH/day
5 days
After laatste pil
GnRH antagonist
Sd 6
hCG OPU ET
PIL ( ≥ 10 days)
Cd2-3
Menstr.
Outcomes
Primary outcome
•Ongoing pregnancy rate
Secondary outcomes
• Clinical pregnancy
• Biochemical pregnancy
• Multiple pregnancy
• Mmiscarriage rate,
• Total FSH/HMG doses used for ovarian stimulation,
• Cancellation rate
• No. oocytes retrieved, no. metaphase II oocytes,
• Fertilization rate
• No. embryos obtained, embryo transfers, embryos frozen
• Drop-out rate
Analysis
Sample size calculation
• Non inferiority design
• Considering an ongoing pregnancy rate of 15 % in both treatment
groups, with an alpha of 5% and a beta of 20%, 197 patients per
group were required to exclude a difference of 10% to the determent
of the mild protocol.
• preplanned blinded interim analysis was performed when 200 women
had completed follow-up
Intention to treat
Trial registeration: NTR2788
Mild stimulation Conventional
stimulation
394 women randomized
Lost to follow-up/drop out (n=16)
Discontinued intervention (n= 43)
1 woman discontinue dthe intervention: no suppression
26 Women cancelled due to poor ovarian response & 2
women changed to IUI
4 no oocytes/MII
10 fertilization failure
Lost to follow-up/drop out (n=18)
Discontinued intervention (n= 56)
3 women discontinued the intervention: spontaneous
ovulation/no suppression/ financial reason
35 Women cancelled due to poor ovarian response & 2 women
changed to IUI
4 no oocytes/MII
12 cycles with fertilization failure
Received allocated intervention:191
Did not receive allocated intervention: 6
2 women antagonist was not available,
1 declined consent,
1 insisted on sex selection,
1 had fibroids
Received allocated intervention:195
Did not receive allocated
intervention:2
1 woman received fault drug,
1 decline their consent,
Flow chart
Allocation
Follow up
Analysis
Analyzed : ITT: 197 Analyzed : ITT: 197
Baseline characteristics
Mild stimulation
(N=197)
conventional stimulation
(N=197)
Age in years (µ ±SD) 36.52± 3,963 36.63±4.287
BMI in Kg/m2
(µ ±SD) 27.19±4.486 27.45±5.282
D. Infertility in years ( µ ±SD) 9.43±5.6 9.28±5.7
Primary infertility, n (%) 143 (74.9) 138 (71.9)
AFC (µ ±SD) 6.2±2.8 6.5± 2.9
FSH (µ±SD) 11.4±4.3 10.5±4.0
E2(µ±SD) 43.8±22.6 42.8±25.7
AMH (µ ±SD) (n= 301) 0.52±0.62 0.6±0.66
Baseline characteristics
Mild stimulation
(N=197)
Conventional stimulation
(N=197)
poor ovarian response
Expected n (%) 143 (74.9) 145 (75.5)
Non expected n (%) 48 (25.1) 47 (24.5)
Previous IVF/ICSI cycles
Yes 89 (47.6%) 94 (50.3)
No 98 (52.4) 93 (49.7)
Causes of infertility, n (%)
Diminished ovarian reserve (IOF) 99 (51.8) 98 (52.0)
IOF + Poor semen quality 47 (24.6) 46 (24)
IOF+ Tubal 16 (8.4) 11 (5.7)
IOF+ Endometriosis 5.0 (2.6) 5.0 (2.6)
IOF+ Multiple factors 16 (8.4) 22 (11.5)
IOF+ Others (..i.e. failed IUI) 8.0 (4.1) 10 (5.2)
Pregnancy outcomes
Mild ovarian
stimulation
(N=197)
Conventional
stimulation
(N=197)
RR (95% CI)
Ongoing pregnancy rate, n (%) 23 (12) 28 (14.6) 0.82 (0.49-1.37)
Clinical pregnancy rate, n (%) 30 (15.7) 35 (18.2) 0.86 (0.55-1.34)
Biochemical pregnancy rate, n (%) 41 (21.5) 38 (19.8) 1.08 (0.73- 1.60)
Early Miscarriage rate, n (%) 7.0 (23) 7.0 (20) 1.0 (0.36-2.80)
Multiple pregnancy rate 2.0 (6.0) 2.0 (5.0) 1.0 (0.14- 7.03)
Ovarian stimulation outcomes
Mild stimulation
(N=197)
Conventional
stimulation (N= 197)
p
No. of stimulation days ( µ ±SD) 95% CI) 8.9±2.6 10.2± 2.5 0.00
Total amount of FSH ( µ ±SD) 1394.4 ±366.4 ---
0.00
Total amount of HMG (µ ±SD) ----- 4852.4±3650.6
No. cycle cancellation rate due to poor ovarian
response, n (% )
35 (18.7) 26 (13.9) 0.32
No. of follicles ≥ 15 mm on hCG day ( µ ±SD) 3.4± 3.0 4.7± 3.6 0.06
Ovarian stimulation outcomes
Mild stimulation
(n=197)
Conventional
stimulation
(n=197)
p
No. of oocytes (µ ± SD) 3.58 ± 3.7 5.2 ± 4.1 0.59
No. of MII oocytes (µ± SD) 2.8±3.0 4.2±3.7 0.01
Fertilization rate (µ ± SD) 2.4±2.6 3.5±3.1 0.39
Total number of embryos 349 365
No. of top quality embryos (95% CI) 0.54 (0.37- 0.71) 0.75 (0.51-1.0) 0.94
No. of embryos transferred (µ ± SD) 1.5±1.4 1.7±1.2 0.056
No. embryos frozen (µ ± SD) 0.82±1.1 0.64±1.9 0.45
Summary
• Mild ovarian stimulation is non-inferior to conventional ovarian
stimulation in terms of pregnancy outcomes
• Mild ovarian stimulation is associated with shorter duration of stimulation
and lower amount of gonadotropins.
• Mild ovarian stimulation is associated with less MII oocytes.
Take home message
Mild ovarian stimulation is the preferred alternative to
conventional stimulation in women with poor reserve
undergoing IVF treatment
Acknowledgment
Dr. M. Van Wely
Dr. M. Mochtar
Prof. F.van der Veen
Prof. Dr. Tahereh Madani
Dr. Nadia Jahangiri
Dr. Shabnam Khodabakhshi
Prof. Dr. M. Akhondi
Dr. S. Abouzar
Prof. Dr. Marwan Halabi
Prof. Dr. S.Khattab
Prof. Dr. Ismail .Aboulfoutouh
Dr. Maged El-mohamedy
Dr. Eman Kamal shoair
Prof. Dr. Ahmed Youssef Rizk
m.a.youssef@amc.uva.nl
Mild stimulation

More Related Content

What's hot

Mirena: AN ALTERNATIVE TO HYSTERECTOMY
Mirena: AN ALTERNATIVE TO HYSTERECTOMYMirena: AN ALTERNATIVE TO HYSTERECTOMY
Mirena: AN ALTERNATIVE TO HYSTERECTOMY
Dr Nupur Gupta High Risk Obstetrician
 
Luteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ARTLuteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ART
Sandro Esteves
 
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Lifecare Centre
 
BỆNH TIM MẠCH VÀ THAI KỲ
BỆNH TIM MẠCH VÀ THAI KỲBỆNH TIM MẠCH VÀ THAI KỲ
BỆNH TIM MẠCH VÀ THAI KỲ
SoM
 
Day 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transferDay 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transfer
Hesham Al-Inany
 
Laparoscopy 1
Laparoscopy  1Laparoscopy  1
Laparoscopy 1
guest9dc181
 
Ultra Short, Highly Economic and Effective Protocol For ICSI Patients
Ultra Short, Highly Economic and Effective Protocol For ICSI PatientsUltra Short, Highly Economic and Effective Protocol For ICSI Patients
Ultra Short, Highly Economic and Effective Protocol For ICSI Patients
Mohamed Walaa El Deeb
 
Unexplained infertility astrakhan webinar copy
Unexplained infertility astrakhan webinar   copyUnexplained infertility astrakhan webinar   copy
Unexplained infertility astrakhan webinar copy
Akram Shalabi
 
Ivf necessary element in gynaecology
Ivf necessary element in gynaecologyIvf necessary element in gynaecology
Ivf necessary element in gynaecology
drhemantzaveri
 
Unlocking I.V.F Services Redefining the New Normal Dr Sharda Jain
Unlocking I.V.F Services Redefining the New Normal Dr Sharda Jain Unlocking I.V.F Services Redefining the New Normal Dr Sharda Jain
Unlocking I.V.F Services Redefining the New Normal Dr Sharda Jain
Lifecare Centre
 
TSH and infertility
TSH and infertilityTSH and infertility
TSH and infertility
Dr Karthik Balachandran
 
Senturk, lm emas webinar infertility and hyperandrogenism_20181205
Senturk, lm emas webinar infertility and hyperandrogenism_20181205Senturk, lm emas webinar infertility and hyperandrogenism_20181205
Senturk, lm emas webinar infertility and hyperandrogenism_20181205
TrkiyeMenopozVeOsteo
 
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVFLuteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
Dr.Laxmi Agrawal Shrikhande
 
unexplained Recurrent miscarriages .. practical approach
unexplained Recurrent miscarriages .. practical approachunexplained Recurrent miscarriages .. practical approach
unexplained Recurrent miscarriages .. practical approach
Iftikharsadique
 
Unexplained Infertility (1)
Unexplained Infertility (1)Unexplained Infertility (1)
Unexplained Infertility (1)
guest7f0a3a
 
Complete Guide To Infertility
Complete Guide To InfertilityComplete Guide To Infertility
Complete Guide To Infertility
Dr.Laxmi Agrawal Shrikhande
 
Unexplained Infertility
Unexplained InfertilityUnexplained Infertility
Unexplained Infertility
guest7f0a3a
 
Repeated Pregnancy Loss in First Trimester
Repeated Pregnancy Loss in First TrimesterRepeated Pregnancy Loss in First Trimester
Repeated Pregnancy Loss in First Trimester
Sujoy Dasgupta
 
2014 07 01 universal thyroid screening
2014 07 01 universal thyroid screening2014 07 01 universal thyroid screening
2014 07 01 universal thyroid screening
mothersafe
 
Epidemiology of Recurrent Pregnancy Loss
Epidemiology of Recurrent Pregnancy LossEpidemiology of Recurrent Pregnancy Loss
Epidemiology of Recurrent Pregnancy Loss
Kirtan Vyas
 

What's hot (20)

Mirena: AN ALTERNATIVE TO HYSTERECTOMY
Mirena: AN ALTERNATIVE TO HYSTERECTOMYMirena: AN ALTERNATIVE TO HYSTERECTOMY
Mirena: AN ALTERNATIVE TO HYSTERECTOMY
 
Luteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ARTLuteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ART
 
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain
 
BỆNH TIM MẠCH VÀ THAI KỲ
BỆNH TIM MẠCH VÀ THAI KỲBỆNH TIM MẠCH VÀ THAI KỲ
BỆNH TIM MẠCH VÀ THAI KỲ
 
Day 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transferDay 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transfer
 
Laparoscopy 1
Laparoscopy  1Laparoscopy  1
Laparoscopy 1
 
Ultra Short, Highly Economic and Effective Protocol For ICSI Patients
Ultra Short, Highly Economic and Effective Protocol For ICSI PatientsUltra Short, Highly Economic and Effective Protocol For ICSI Patients
Ultra Short, Highly Economic and Effective Protocol For ICSI Patients
 
Unexplained infertility astrakhan webinar copy
Unexplained infertility astrakhan webinar   copyUnexplained infertility astrakhan webinar   copy
Unexplained infertility astrakhan webinar copy
 
Ivf necessary element in gynaecology
Ivf necessary element in gynaecologyIvf necessary element in gynaecology
Ivf necessary element in gynaecology
 
Unlocking I.V.F Services Redefining the New Normal Dr Sharda Jain
Unlocking I.V.F Services Redefining the New Normal Dr Sharda Jain Unlocking I.V.F Services Redefining the New Normal Dr Sharda Jain
Unlocking I.V.F Services Redefining the New Normal Dr Sharda Jain
 
TSH and infertility
TSH and infertilityTSH and infertility
TSH and infertility
 
Senturk, lm emas webinar infertility and hyperandrogenism_20181205
Senturk, lm emas webinar infertility and hyperandrogenism_20181205Senturk, lm emas webinar infertility and hyperandrogenism_20181205
Senturk, lm emas webinar infertility and hyperandrogenism_20181205
 
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVFLuteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
Luteal phase support in IUI and ART | Dr. Laxmi Shrikhande | ShrikhandeIVF
 
unexplained Recurrent miscarriages .. practical approach
unexplained Recurrent miscarriages .. practical approachunexplained Recurrent miscarriages .. practical approach
unexplained Recurrent miscarriages .. practical approach
 
Unexplained Infertility (1)
Unexplained Infertility (1)Unexplained Infertility (1)
Unexplained Infertility (1)
 
Complete Guide To Infertility
Complete Guide To InfertilityComplete Guide To Infertility
Complete Guide To Infertility
 
Unexplained Infertility
Unexplained InfertilityUnexplained Infertility
Unexplained Infertility
 
Repeated Pregnancy Loss in First Trimester
Repeated Pregnancy Loss in First TrimesterRepeated Pregnancy Loss in First Trimester
Repeated Pregnancy Loss in First Trimester
 
2014 07 01 universal thyroid screening
2014 07 01 universal thyroid screening2014 07 01 universal thyroid screening
2014 07 01 universal thyroid screening
 
Epidemiology of Recurrent Pregnancy Loss
Epidemiology of Recurrent Pregnancy LossEpidemiology of Recurrent Pregnancy Loss
Epidemiology of Recurrent Pregnancy Loss
 

Similar to Mild ovarian stimulation in women with poor ovarian reeserve (PRIMA)

Prima IVF poor responders
Prima IVF  poor respondersPrima IVF  poor responders
Prima IVF poor responders
Hesham Al-Inany
 
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
IVF-Mohamed Youssef AF
 
ovulation induction protocols update 2014
ovulation induction protocols update 2014ovulation induction protocols update 2014
ovulation induction protocols update 2014
Hesham Al-Inany
 
15. Unexplained infertility (1).ppt
15. Unexplained infertility (1).ppt15. Unexplained infertility (1).ppt
15. Unexplained infertility (1).ppt
abdalla
 
(마더세이프라운드) Thyroid disease in pregnancy
(마더세이프라운드) Thyroid disease in pregnancy (마더세이프라운드) Thyroid disease in pregnancy
(마더세이프라운드) Thyroid disease in pregnancy
mothersafe
 
Optimizing iui results
Optimizing iui resultsOptimizing iui results
Optimizing iui results
vandana bansal
 
Infertility.(By Craig)
Infertility.(By Craig)Infertility.(By Craig)
Infertility.(By Craig)
drmcbansal
 
Is there a place for progesterone in the management of miscarriage?
Is there a place for progesterone in the management of miscarriage?Is there a place for progesterone in the management of miscarriage?
Is there a place for progesterone in the management of miscarriage?
drmattprior
 
4G ovarian stimulation
4G ovarian stimulation 4G ovarian stimulation
4G ovarian stimulation
Hesham Al-Inany
 
Pragmatic Open-Label Randomized Trial of Pre-Exposure Prophylaxis: the PROUD ...
Pragmatic Open-Label Randomized Trial of Pre-Exposure Prophylaxis: the PROUD ...Pragmatic Open-Label Randomized Trial of Pre-Exposure Prophylaxis: the PROUD ...
Pragmatic Open-Label Randomized Trial of Pre-Exposure Prophylaxis: the PROUD ...
Office of HIV Planning
 
4G O.I.pptx
4G O.I.pptx4G O.I.pptx
4G O.I.pptx
Hesham Al-Inany
 
P 432
P 432P 432
Secrets for success of Intra Uterine Insemination (IUI)
Secrets for success of Intra Uterine Insemination (IUI)Secrets for success of Intra Uterine Insemination (IUI)
Secrets for success of Intra Uterine Insemination (IUI)
Anu Test Tube Baby Centre
 
ART options for poor responders.pdf
ART options for poor responders.pdfART options for poor responders.pdf
ART options for poor responders.pdf
Marmara University School of Medicine
 
medical management of infertility,think before surgery!!!!
medical management of infertility,think before surgery!!!!medical management of infertility,think before surgery!!!!
medical management of infertility,think before surgery!!!!
ShitalSavaliya1
 
Adjuvant therapy
Adjuvant therapyAdjuvant therapy
Adjuvant therapy
Hesham Al-Inany
 
Journal club
Journal clubJournal club
Journal club
Arsla Memon
 
Oncofertility 박찬우
Oncofertility 박찬우Oncofertility 박찬우
Oncofertility 박찬우
mothersafe
 
ICSI for all
ICSI for allICSI for all
ICSI for all
Dr. Jyoti Malik
 
IVF Outcome in Women with PCOS, PCO and Normal Ovarian Morphology
IVF Outcome in Women with PCOS, PCO and Normal Ovarian MorphologyIVF Outcome in Women with PCOS, PCO and Normal Ovarian Morphology
IVF Outcome in Women with PCOS, PCO and Normal Ovarian Morphology
Alex Swanton
 

Similar to Mild ovarian stimulation in women with poor ovarian reeserve (PRIMA) (20)

Prima IVF poor responders
Prima IVF  poor respondersPrima IVF  poor responders
Prima IVF poor responders
 
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
 
ovulation induction protocols update 2014
ovulation induction protocols update 2014ovulation induction protocols update 2014
ovulation induction protocols update 2014
 
15. Unexplained infertility (1).ppt
15. Unexplained infertility (1).ppt15. Unexplained infertility (1).ppt
15. Unexplained infertility (1).ppt
 
(마더세이프라운드) Thyroid disease in pregnancy
(마더세이프라운드) Thyroid disease in pregnancy (마더세이프라운드) Thyroid disease in pregnancy
(마더세이프라운드) Thyroid disease in pregnancy
 
Optimizing iui results
Optimizing iui resultsOptimizing iui results
Optimizing iui results
 
Infertility.(By Craig)
Infertility.(By Craig)Infertility.(By Craig)
Infertility.(By Craig)
 
Is there a place for progesterone in the management of miscarriage?
Is there a place for progesterone in the management of miscarriage?Is there a place for progesterone in the management of miscarriage?
Is there a place for progesterone in the management of miscarriage?
 
4G ovarian stimulation
4G ovarian stimulation 4G ovarian stimulation
4G ovarian stimulation
 
Pragmatic Open-Label Randomized Trial of Pre-Exposure Prophylaxis: the PROUD ...
Pragmatic Open-Label Randomized Trial of Pre-Exposure Prophylaxis: the PROUD ...Pragmatic Open-Label Randomized Trial of Pre-Exposure Prophylaxis: the PROUD ...
Pragmatic Open-Label Randomized Trial of Pre-Exposure Prophylaxis: the PROUD ...
 
4G O.I.pptx
4G O.I.pptx4G O.I.pptx
4G O.I.pptx
 
P 432
P 432P 432
P 432
 
Secrets for success of Intra Uterine Insemination (IUI)
Secrets for success of Intra Uterine Insemination (IUI)Secrets for success of Intra Uterine Insemination (IUI)
Secrets for success of Intra Uterine Insemination (IUI)
 
ART options for poor responders.pdf
ART options for poor responders.pdfART options for poor responders.pdf
ART options for poor responders.pdf
 
medical management of infertility,think before surgery!!!!
medical management of infertility,think before surgery!!!!medical management of infertility,think before surgery!!!!
medical management of infertility,think before surgery!!!!
 
Adjuvant therapy
Adjuvant therapyAdjuvant therapy
Adjuvant therapy
 
Journal club
Journal clubJournal club
Journal club
 
Oncofertility 박찬우
Oncofertility 박찬우Oncofertility 박찬우
Oncofertility 박찬우
 
ICSI for all
ICSI for allICSI for all
ICSI for all
 
IVF Outcome in Women with PCOS, PCO and Normal Ovarian Morphology
IVF Outcome in Women with PCOS, PCO and Normal Ovarian MorphologyIVF Outcome in Women with PCOS, PCO and Normal Ovarian Morphology
IVF Outcome in Women with PCOS, PCO and Normal Ovarian Morphology
 

Recently uploaded

Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
Swastik Ayurveda
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
chandankumarsmartiso
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Donc Test
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 

Recently uploaded (20)

Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 

Mild ovarian stimulation in women with poor ovarian reeserve (PRIMA)

  • 1. Mild versus conventional ovarian stimulation for IVF/ICSI treatment in women with poor ovarian reserve (PRIMA Trial) Youssef M.A.F.M Al-Inany H.
  • 2. Background • The age of women giving birth to their first child is rising • Older women have decreased fecundity • Consequently, more older women will request IVF of poor ovarian response is 9-24%
  • 3. Background Broekmans et al. 2009 Endocrine Reviews
  • 4. Conventional ovarian stimulationMild ovarian stimulation Quality versus Quantity
  • 5. Aim of PRIMA trial • To evaluate the effectiveness and safety of a mild stimulation IVF versus a conventional simulation IVF in women with poor ovarian reserve undergoing IVF treatment
  • 6. 394 couples poor ovarian reserve 197 couples Mild IVF 197 couples Conventional IVF treatmenttime OCP+ 150 IU FSH + GnRH antagonist Mid-Luteal Long GnRH agonist + 450 IU HMG Ongoing Pregnancy recruitme nt endpoint PRIMA trial design
  • 7. Couples Inclusion criteria •Women with an indication for IVF •Aged > 35 years •and/or women who have FSH >10 IU/ml •and/or women who have AFC (< 7 follicles) •Women who responded poorly during their 1st IVF cycle irrespective of their age. Exclusion criteria •Women with pre-existing medical conditions, •Women > 43 years old; •Women with uterine anomalies; polycystic ovary syndrome and anovulation
  • 8. 450 IU HMG /day mid-luteal GnRH agonist hCG OPU ET Menstr.  Mild Ovarian stimulation IVF  Conventional Ovarian stimulation/IVF Interventions 150 IU FSH/day 5 days After laatste pil GnRH antagonist Sd 6 hCG OPU ET PIL ( ≥ 10 days) Cd2-3 Menstr.
  • 9. Outcomes Primary outcome •Ongoing pregnancy rate Secondary outcomes • Clinical pregnancy • Biochemical pregnancy • Multiple pregnancy • Mmiscarriage rate, • Total FSH/HMG doses used for ovarian stimulation, • Cancellation rate • No. oocytes retrieved, no. metaphase II oocytes, • Fertilization rate • No. embryos obtained, embryo transfers, embryos frozen • Drop-out rate
  • 10. Analysis Sample size calculation • Non inferiority design • Considering an ongoing pregnancy rate of 15 % in both treatment groups, with an alpha of 5% and a beta of 20%, 197 patients per group were required to exclude a difference of 10% to the determent of the mild protocol. • preplanned blinded interim analysis was performed when 200 women had completed follow-up Intention to treat Trial registeration: NTR2788
  • 11. Mild stimulation Conventional stimulation 394 women randomized Lost to follow-up/drop out (n=16) Discontinued intervention (n= 43) 1 woman discontinue dthe intervention: no suppression 26 Women cancelled due to poor ovarian response & 2 women changed to IUI 4 no oocytes/MII 10 fertilization failure Lost to follow-up/drop out (n=18) Discontinued intervention (n= 56) 3 women discontinued the intervention: spontaneous ovulation/no suppression/ financial reason 35 Women cancelled due to poor ovarian response & 2 women changed to IUI 4 no oocytes/MII 12 cycles with fertilization failure Received allocated intervention:191 Did not receive allocated intervention: 6 2 women antagonist was not available, 1 declined consent, 1 insisted on sex selection, 1 had fibroids Received allocated intervention:195 Did not receive allocated intervention:2 1 woman received fault drug, 1 decline their consent, Flow chart Allocation Follow up Analysis Analyzed : ITT: 197 Analyzed : ITT: 197
  • 12. Baseline characteristics Mild stimulation (N=197) conventional stimulation (N=197) Age in years (µ ±SD) 36.52± 3,963 36.63±4.287 BMI in Kg/m2 (µ ±SD) 27.19±4.486 27.45±5.282 D. Infertility in years ( µ ±SD) 9.43±5.6 9.28±5.7 Primary infertility, n (%) 143 (74.9) 138 (71.9) AFC (µ ±SD) 6.2±2.8 6.5± 2.9 FSH (µ±SD) 11.4±4.3 10.5±4.0 E2(µ±SD) 43.8±22.6 42.8±25.7 AMH (µ ±SD) (n= 301) 0.52±0.62 0.6±0.66
  • 13. Baseline characteristics Mild stimulation (N=197) Conventional stimulation (N=197) poor ovarian response Expected n (%) 143 (74.9) 145 (75.5) Non expected n (%) 48 (25.1) 47 (24.5) Previous IVF/ICSI cycles Yes 89 (47.6%) 94 (50.3) No 98 (52.4) 93 (49.7) Causes of infertility, n (%) Diminished ovarian reserve (IOF) 99 (51.8) 98 (52.0) IOF + Poor semen quality 47 (24.6) 46 (24) IOF+ Tubal 16 (8.4) 11 (5.7) IOF+ Endometriosis 5.0 (2.6) 5.0 (2.6) IOF+ Multiple factors 16 (8.4) 22 (11.5) IOF+ Others (..i.e. failed IUI) 8.0 (4.1) 10 (5.2)
  • 14. Pregnancy outcomes Mild ovarian stimulation (N=197) Conventional stimulation (N=197) RR (95% CI) Ongoing pregnancy rate, n (%) 23 (12) 28 (14.6) 0.82 (0.49-1.37) Clinical pregnancy rate, n (%) 30 (15.7) 35 (18.2) 0.86 (0.55-1.34) Biochemical pregnancy rate, n (%) 41 (21.5) 38 (19.8) 1.08 (0.73- 1.60) Early Miscarriage rate, n (%) 7.0 (23) 7.0 (20) 1.0 (0.36-2.80) Multiple pregnancy rate 2.0 (6.0) 2.0 (5.0) 1.0 (0.14- 7.03)
  • 15. Ovarian stimulation outcomes Mild stimulation (N=197) Conventional stimulation (N= 197) p No. of stimulation days ( µ ±SD) 95% CI) 8.9±2.6 10.2± 2.5 0.00 Total amount of FSH ( µ ±SD) 1394.4 ±366.4 --- 0.00 Total amount of HMG (µ ±SD) ----- 4852.4±3650.6 No. cycle cancellation rate due to poor ovarian response, n (% ) 35 (18.7) 26 (13.9) 0.32 No. of follicles ≥ 15 mm on hCG day ( µ ±SD) 3.4± 3.0 4.7± 3.6 0.06
  • 16. Ovarian stimulation outcomes Mild stimulation (n=197) Conventional stimulation (n=197) p No. of oocytes (µ ± SD) 3.58 ± 3.7 5.2 ± 4.1 0.59 No. of MII oocytes (µ± SD) 2.8±3.0 4.2±3.7 0.01 Fertilization rate (µ ± SD) 2.4±2.6 3.5±3.1 0.39 Total number of embryos 349 365 No. of top quality embryos (95% CI) 0.54 (0.37- 0.71) 0.75 (0.51-1.0) 0.94 No. of embryos transferred (µ ± SD) 1.5±1.4 1.7±1.2 0.056 No. embryos frozen (µ ± SD) 0.82±1.1 0.64±1.9 0.45
  • 17. Summary • Mild ovarian stimulation is non-inferior to conventional ovarian stimulation in terms of pregnancy outcomes • Mild ovarian stimulation is associated with shorter duration of stimulation and lower amount of gonadotropins. • Mild ovarian stimulation is associated with less MII oocytes.
  • 18. Take home message Mild ovarian stimulation is the preferred alternative to conventional stimulation in women with poor reserve undergoing IVF treatment
  • 19. Acknowledgment Dr. M. Van Wely Dr. M. Mochtar Prof. F.van der Veen Prof. Dr. Tahereh Madani Dr. Nadia Jahangiri Dr. Shabnam Khodabakhshi Prof. Dr. M. Akhondi Dr. S. Abouzar Prof. Dr. Marwan Halabi Prof. Dr. S.Khattab Prof. Dr. Ismail .Aboulfoutouh Dr. Maged El-mohamedy Dr. Eman Kamal shoair Prof. Dr. Ahmed Youssef Rizk

Editor's Notes

  1. Noem kosten effect; titel naam en tijd plaatje